{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:52:37Z","timestamp":1790621557560,"version":"4.1.0"},"reference-count":46,"publisher":"BMJ","issue":"1","funder":[{"name":"PsiOxus Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40425-017-0277-7","type":"journal-article","created":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T03:37:56Z","timestamp":1504323476000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection"],"prefix":"10.1136","volume":"5","author":[{"given":"Rocio","family":"Garcia-Carbonero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Osman-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Bozada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Len","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Beadle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Alvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Champion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,9,19]]},"reference":[{"key":"277_CR1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/bjc.2015.481","volume":"114","author":"LW Seymour","year":"2016","unstructured":"Seymour LW, Fisher KD. Oncolytic viruses: finally delivering. Br J Cancer. 2016;114:357\u201361.","journal-title":"Br J Cancer"},{"key":"277_CR2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fonc.2014.00188","volume":"4","author":"N Woller","year":"2014","unstructured":"Woller N, Gurlevik E, Ureche CI, Schumacher A, Kuhnel F. Oncolytic viruses as anticancer vaccines. Front Oncol. 2014;4:188.","journal-title":"Front Oncol"},{"key":"277_CR3","unstructured":"Amgen Inc. Food and Drug Administration (FDA). US prescribing information. IMLYGIC (talimogene laherparepvec). 2015. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/UCM469575.pdf . Accessed 4 Nov 2016."},{"key":"277_CR4","unstructured":"Amgen Inc. European Medicines Agency. Imlygic EPAR Product Information. 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002771\/WC500201079.pdf . Accessed 9 Dec 2016."},{"key":"277_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/586389","volume":"2012","author":"M Bauzon","year":"2012","unstructured":"Bauzon M, Hermiston TW. Oncolytic viruses: the power of directed evolution. Adv Virol. 2012;2012:1\u20135.","journal-title":"Adv Virol"},{"key":"277_CR6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/156800907780058862","volume":"7","author":"AM Crompton","year":"2007","unstructured":"Crompton AM, Kirn DH. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets. 2007;7:133\u20139.","journal-title":"Curr Cancer Drug Targets"},{"key":"277_CR7","doi-asserted-by":"crossref","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","volume":"3","author":"I Kuhn","year":"2008","unstructured":"Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One. 2008;3:e2409.","journal-title":"PLoS One"},{"key":"277_CR8","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/gt.2009.69","volume":"16","author":"M Bauzon","year":"2009","unstructured":"Bauzon M, Jin F, Kretschmer P, Hermiston T. In vitro analysis of cidofovir and genetically engineered TK expression as potential approaches for the intervention of ColoAd1-based treatment of cancer. Gene Ther. 2009;16:1169\u201374.","journal-title":"Gene Ther"},{"key":"277_CR9","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/mt.2015.233","volume":"24","author":"A Tedcastle","year":"2016","unstructured":"Tedcastle A, Illingworth S, Brown A, Seymour LW, Fisher KD. Actin-resistant DNAse I expression from oncolytic adenovirus enadenotucirev enhances its intratumoral spread and reduces tumor growth. Mol Ther. 2016;24:796\u2013804.10.","journal-title":"Mol Ther"},{"key":"277_CR10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.omto.2016.11.003","volume":"4","author":"A Dyer","year":"2016","unstructured":"Dyer A, Ying D, Calderon H, Illingworth S, Kueberuwa G, Tedcastle A, et al. Oncolytic group B adenovirus enadenotucirev mediates oncosis-like cell death with membrane permeabilisation and release of inflammatory mediators. Mol Ther Oncolytics. 2016;4:18\u201330.","journal-title":"Mol Ther Oncolytics"},{"key":"277_CR11","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.omto.2017.03.003","volume":"5","author":"S Illingworth","year":"2017","unstructured":"Illingworth S, Di Y, Bauzon M, Lei J, Duffy MR, Alvis S, Champion B, Lieber A, Hermiston T, Seymour LW, Fisher K. Preclinical safety studies of enadenotucirev, a chimeric group B human-specific oncolytic adenovirus. Mol Ther Oncolytics. 2017;5:62\u201374.","journal-title":"Mol Ther Oncolytics"},{"issue":"5","key":"277_CR12","doi-asserted-by":"crossref","first-page":"e0177810","DOI":"10.1371\/journal.pone.0177810","volume":"12","author":"M Marino","year":"2017","unstructured":"Marino M, Illingworth S, Kodialbail P, Patel A, Calderon H, Lear R, Fisher KD, Champion BR, Brown ACN. Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. PLoS One. 2017;12(5):e0177810.","journal-title":"PLoS One"},{"key":"277_CR13","first-page":"74","volume":"4","author":"ZS Guo","year":"2014","unstructured":"Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 2014;4:74.","journal-title":"Front Oncol"},{"key":"277_CR14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","volume":"14","author":"BD Lichty","year":"2014","unstructured":"Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14:559\u201367.","journal-title":"Nat Rev Cancer"},{"issue":"Suppl 1","key":"277_CR15","first-page":"73","volume":"4","author":"H Calderon","year":"2016","unstructured":"Calderon H, Illingworth S, Brown A, Fisher K, Seymour L, Champion B. Selective activation of innate immune responses by the Ad11\/Ad3 chimeric oncolytic group B adenovirus enadenotucirev. J Immunother Cancer. 2016;4(Suppl 1):73.","journal-title":"J Immunother Cancer"},{"key":"277_CR16","doi-asserted-by":"crossref","first-page":"805629","DOI":"10.1155\/2012\/805629","volume":"2012","author":"MS Ferguson","year":"2012","unstructured":"Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles. Adv Virol. 2012;2012:805629.","journal-title":"Adv Virol"},{"key":"277_CR17","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;34:2619\u201326.","journal-title":"J Clin Oncol"},{"key":"277_CR18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","volume":"477","author":"CJ Breitbach","year":"2011","unstructured":"Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011;477:99\u2013102.","journal-title":"Nature"},{"key":"277_CR19","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/sj.gt.3301424","volume":"8","author":"J Nemunaitis","year":"2001","unstructured":"Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 2001;8:746\u201359.","journal-title":"Gene Ther"},{"key":"277_CR20","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","volume":"113","author":"RC Carlisle","year":"2009","unstructured":"Carlisle RC, Di Y, Cerny AM, Sonnen AF, Sim RB, Green NK, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009;113:1909\u201318.","journal-title":"Blood"},{"key":"277_CR21","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2012.257","volume":"21","author":"P Sampath","year":"2013","unstructured":"Sampath P, Li J, Hou W, Chen H, Bartlett DL, Thorne SH. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther. 2013;21:620\u20138.","journal-title":"Mol Ther"},{"key":"277_CR22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2006.01.003","volume":"14","author":"M Lyons","year":"2006","unstructured":"Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, Bazan-Peregrino M, et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther. 2006;14:118\u201328.","journal-title":"Mol Ther"},{"key":"277_CR23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1089\/hum.2009.028","volume":"20","author":"K Doronin","year":"2009","unstructured":"Doronin K, Shashkova EV, May SM, Hofherr SE, Barry MA. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther. 2009;20:975\u201388.","journal-title":"Hum Gene Ther"},{"key":"277_CR24","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-14-1770","volume":"21","author":"V Roulstone","year":"2015","unstructured":"Roulstone V, Khan K, Pandha HS, Rudman S, Coffey M, Gill GM, et al. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clin Cancer Res. 2015;21:1305\u201312.","journal-title":"Clin Cancer Res"},{"key":"277_CR25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/gt.2014.2","volume":"21","author":"Y Di","year":"2014","unstructured":"Di Y, Seymour L, Fisher K. Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood. Gene Ther. 2014;21:440\u20133.","journal-title":"Gene Ther"},{"key":"277_CR26","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","volume":"77","author":"R Vogels","year":"2003","unstructured":"Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003;77:8263\u201371.","journal-title":"J Virol"},{"key":"277_CR27","doi-asserted-by":"crossref","first-page":"13207","DOI":"10.1128\/JVI.78.23.13207-13215.2004","volume":"78","author":"L Holterman","year":"2004","unstructured":"Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen J, Kaspers J, et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol. 2004;78:13207\u201315.","journal-title":"J Virol"},{"key":"277_CR28","first-page":"3491","volume":"58","author":"Y Naito","year":"1998","unstructured":"Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491\u20134.","journal-title":"Cancer Res"},{"key":"277_CR29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"277_CR30","unstructured":"Knipe DM, Howley PM. Fields Virology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2013."},{"key":"277_CR31","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/bjc.2015.213","volume":"113","author":"L Smedt De","year":"2015","unstructured":"De Smedt L, Lemahieu J, Palmans S, Govaere O, Tousseyn T, Van Cutsem E, et al. Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis. Br J Cancer. 2015;113:500\u20139.","journal-title":"Br J Cancer"},{"key":"277_CR32","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0960-9822(00)00130-5","volume":"4","author":"E Donnadieu","year":"1994","unstructured":"Donnadieu E, Bismuth G, Trautmann A. Antigen recognition by helper T cells elicits a sequence of distinct changes of their shape and intracellular calcium. Curr Biol. 1994;4:584\u201395.","journal-title":"Curr Biol"},{"key":"277_CR33","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1080\/21645515.2015.1049779","volume":"11","author":"RH Pierce","year":"2015","unstructured":"Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE. In-situ tumor vaccination: bringing the fight to the tumor. Hum Vaccin Immunother. 2015;11:1901\u20139.","journal-title":"Hum Vaccin Immunother"},{"key":"277_CR34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fimmu.2013.00292","volume":"4","author":"G Darrasse-Jeze","year":"2013","unstructured":"Darrasse-Jeze G, Podsypanina K. How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development. Front Immunol. 2013;4:292.","journal-title":"Front Immunol"},{"key":"277_CR35","doi-asserted-by":"crossref","unstructured":"Calvo E, Gil-Martin M, Machiels J, Rottey S, Cubillo A, Salazar R, et al. A phase I study of enadenotucirev, an oncolytic Ad11\/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumours. Chicago: Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO); 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.3103"},{"key":"277_CR36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymthe.2006.02.011","volume":"14","author":"EJ Small","year":"2006","unstructured":"Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006;14:107\u201317.","journal-title":"Mol Ther"},{"key":"277_CR37","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1158\/1078-0432.CCR-10-1233","volume":"16","author":"C Comins","year":"2010","unstructured":"Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res. 2010;16:5564\u201372.","journal-title":"Clin Cancer Res"},{"key":"277_CR38","doi-asserted-by":"crossref","unstructured":"Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, et al. Phase II trial of intravenous administration of Reolysin(\u00ae) (Reovirus serotype-3-dearing strain) in patients with metastatic melanoma. Mol Ther. 2012;20:1998\u20132003.","DOI":"10.1038\/mt.2012.146"},{"key":"277_CR39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","volume":"19","author":"J Heo","year":"2013","unstructured":"Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med. 2013;19:329\u201336.","journal-title":"Nat Med"},{"key":"277_CR40","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-08-0524","volume":"14","author":"L Vidal","year":"2008","unstructured":"Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008;14:7127\u201337.","journal-title":"Clin Cancer Res"},{"key":"277_CR41","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1158\/1078-0432.CCR-06-0467","volume":"12","author":"PS Yan","year":"2006","unstructured":"Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res. 2006;12:6626\u201336.","journal-title":"Clin Cancer Res"},{"key":"277_CR42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/gastro\/got039","volume":"2","author":"Y Luo","year":"2014","unstructured":"Luo Y, Yu M, Grady WM. Field cancerization in the colon: a role for aberrant DNA methylation? Gastroenterol Rep (Oxf). 2014;2:16\u201320.","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"277_CR43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/intimm\/dxw025","volume":"28","author":"Y Takeuchi","year":"2016","unstructured":"Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. Int Immunol. 2016;28:401\u20139.","journal-title":"Int Immunol"},{"key":"277_CR44","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1158\/1078-0432.CCR-14-2009","volume":"21","author":"JJ Rojas","year":"2015","unstructured":"Rojas JJ, Sampath P, Hou W, Thorne SH. Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clin Cancer Res. 2015;21:5543\u201351.","journal-title":"Clin Cancer Res"},{"key":"277_CR45","first-page":"75","volume":"4","author":"P Sampath","year":"2015","unstructured":"Sampath P, Thorne SH. Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy. Oncolytic Virother. 2015;4:75\u201382.","journal-title":"Oncolytic Virother"},{"key":"277_CR46","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","volume":"22","author":"CE Engeland","year":"2014","unstructured":"Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther. 2014;22:1949\u201359.","journal-title":"Mol Ther"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-017-0277-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:42:47Z","timestamp":1601041367000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-017-0277-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,19]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["277"],"URL":"https:\/\/doi.org\/10.1186\/s40425-017-0277-7","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,19]]},"article-number":"71"}}